Chris Ryan

A dostarlimab-gxly combination was approved for advanced or recurrent endometrial cancer.

The TIL cell therapy OBX-115 received fast track designation from the FDA for locally advanced or metastatic melanoma.

The antibody drug conjugate BNT324/DB-1311 received fast track designation for the potential treatment of unresectable advanced or metastatic castration-resistant prostate cancer with disease progression.

Durable complete responses were observed in patients with TP52-mutated mantle cell lymphoma treated with ibrutinib plus venetoclax.

The CAR T-cell therapy ADI-270 received fast track designation from the FDA for pretreated advanced clear cell renal cell carcinoma.

The failure to improve PFS and OS with tiragolumab plus atezolizumab and chemo in metastatic nonsquamous NSCLC indicates missing the primary end points of the SKYSCRAPER-06 trial.

The resubmission of the biologics license application for cosibelimab for locally advanced or metastatic cutaneous squamous cell carcinoma follows a complete response letter from the FDA in December 2023.

The updated risk evaluation and mitigation strategies for autologous CAR T-cell therapy removed requirements for training and educational materials about the risk for certain toxicities.

PSMA response was linked to improved metastasis-free survival in patients with oligometastatic castration-sensitive prostate cancer.

Frontline durvalumab plus chemotherapy, followed by maintenance durvalumab with or without olaparib improved responses in stage III/IV or recurrent endometrial cancer.

The biologics license application for subcutaneous amivantamab is seeking approval for the treatment of EGFR-positive non-small cell lung cancer.

The FDA approved durvalumab plus carboplatin and paclitaxel, followed by single-agent durvalumab for primary advanced or recurrent dMMR endometrial cancer.

Findings from a retrospective study may shed light on the prognostic value of PD-L1 expression in metastatic papillary renal cell carcinoma.

The priority review granted by the FDA to the supplemental new drug application for osimertinib is seeking approval for its treatment of stage III non-small cell lung cancer with EGFR mutations.

Rates of MRD negativity increased with daratumumab plus VRd in newly diagnosed, transplant-eligible multiple myeloma.

Patients with HR-positive, HER2-low, and -ultralow metastatic breast cancer treated with trastuzumab deruxtecan obtained a PFS benefit vs chemotherapy.

Compared with placebo, osimertinib after definitive chemoradiotherapy improved progression-free survival in locally advanced, EGFR-mutated non–small cell lung cancer.

A breakthrough device designation has been granted by the FDA to Teal Wand, an at-home screening test for cervical cancer.

HPV vaccines in patients under the age of 40 may have lowered rates of HPV-related cancer compared with unvaccinated patients.

The accelerated approval of infigratinib has been withdrawn by the FDA for previously treated, FGFR2-positive, advanced cholangiocarcinoma.

Frontline treatment with pembrolizumab plus trastuzumab/chemotherapy significantly and meaningfully improved overall survival in HER2-positive, unresectable or metastatic gastric/GEJ cancer.

Glecirasib resulted in durable responses with a manageable safety profile for pretreated advanced non-small cell lung cancer with KRAS G12C mutations.

A screening test has been approved by the FDA for adults 45 years of age or older with an average risk for developing colorectal cancer.

Trastuzumab deruxtecan enhanced survival without disease progression compared with chemotherapy in HR-positive, HER2-low metastatic breast cancer after 1 or more lines of endocrine therapy.

The optical imaging agent Lumisight and the Lumicell Direct Visualization System received approval from the FDA for fluorescence imaging in breast cancer.

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

The preference of subcutaneous atezolizumab compared with its intravenous formulation was demonstrated in patients with non–small cell lung cancer treated on the IMscin002 trial.

The new drug application for revumenib is supported by data from the AUGMENT-101 trial of patients with KMT2A-rearranged acute myeloid leukemia or acute lymphoblastic leukemia.

The benefits noted in this exploratory analysis were irrespective of the number of neoadjuvant treatment cycles completed in patients with resectable non-small cell lung cancer.

The safety label for fluorouracil products will now include information about the agent’s use in patients with dihydropyrimidine dehydrogenase deficiency.